Show simple item record

Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins.

dc.contributor.authorFranco, Daniel A
dc.contributor.authorTruran, Seth
dc.contributor.authorWeissig, Volkmar
dc.contributor.authorGuzman-Villanueva, Diana
dc.contributor.authorKaramanova, Nina
dc.contributor.authorSenapati, Subhadip
dc.contributor.authorBurciu, Camelia
dc.contributor.authorRamirez-Alvarado, Marina
dc.contributor.authorBlancas-Mejia, Luis M
dc.contributor.authorLindsay, Stuart
dc.contributor.authorHari, Parameswaran
dc.contributor.authorMigrino, Raymond Q
dc.date.accessioned2016-12-15T21:10:51Z
dc.date.available2016-12-15T21:10:51Z
dc.date.issued2016-06-13
dc.identifier.citationMonosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins. 2016, 5 (6) J Am Heart Assocen
dc.identifier.issn2047-9980
dc.identifier.pmid27412900
dc.identifier.doi10.1161/JAHA.116.003318
dc.identifier.urihttp://hdl.handle.net/10150/621716
dc.description.abstractLight chain amyloidosis (AL) is associated with high mortality, especially in patients with advanced cardiovascular involvement. It is caused by toxicity of misfolded light chain proteins (LC) in vascular, cardiac, and other tissues. There is no treatment to reverse LC tissue toxicity. We tested the hypothesis that nanoliposomes composed of monosialoganglioside, phosphatidylcholine, and cholesterol (GM1 ganglioside-containing nanoliposomes [NLGM1]) can protect against LC-induced human microvascular dysfunction and assess mechanisms behind the protective effect.
dc.description.sponsorshipVeterans Affairs Merit grant [I0 1BX007080]; National Institutes of Health [NIA R21AG044723, GM RO1 071514]; Amyloidosis Foundation; American Heart Association [0855683G]; Carl T. Hayden Medical Research Foundation; Mayo Foundation; Midwestern Universityen
dc.language.isoenen
dc.publisherWILEY-BLACKWELLen
dc.rights© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License.en
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectamyloiden
dc.subjectendotheliumen
dc.subjectnanotechnologyen
dc.subjectoxidant stressen
dc.titleMonosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins.en
dc.typeArticleen
dc.contributor.departmentUniv Arizona, Coll Meden
dc.identifier.journalJournal of the American Heart Associationen
dc.description.noteOpen Access Journalen
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen
refterms.dateFOA2018-07-01T04:44:25Z
html.description.abstractLight chain amyloidosis (AL) is associated with high mortality, especially in patients with advanced cardiovascular involvement. It is caused by toxicity of misfolded light chain proteins (LC) in vascular, cardiac, and other tissues. There is no treatment to reverse LC tissue toxicity. We tested the hypothesis that nanoliposomes composed of monosialoganglioside, phosphatidylcholine, and cholesterol (GM1 ganglioside-containing nanoliposomes [NLGM1]) can protect against LC-induced human microvascular dysfunction and assess mechanisms behind the protective effect.


Files in this item

Thumbnail
Name:
e003318.full.pdf
Size:
1.224Mb
Format:
PDF
Description:
Final Published Version
Download

This item appears in the following Collection(s)

Show simple item record

© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License.
Except where otherwise noted, this item's license is described as © 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License.